Abstract
Background. Bisphosphonates are effective agents for the management of osteoporosis. Their low bioavailability and low potency necessitate frequent administration on an empty stomach, which may reduce compliance. Gastrointestinal intolerance limits maximal dosing. Although intermittent intravenous treatments have been used, the optimal doses and dosing interval have not been systematically explored. Methods. We studied the effects of five regimens of zoledronic acid, the most potent bisphosphonate, on bone turnover and density in 351 postmenopausal women with low bone mineral density in a one-year, randomized, double-blind, placebo-controlled trial. Women received placebo or intravenous zoledronic acid in doses of 0.25 mg, 0.5 mg, or 1 mg at threemonth intervals. In addition, one group received a total annual dose of 4 mg as a single dose, and another received two doses of 2 mg each, six months apart. Lumbar-spine bone mineral density, was the primary end point. Results. There were similar increases in bone mineral density in all the zoledronic acid groups to values for the spine that were 4.3 to 5.1 percent higher than those in the placebo group (P
| Original language | English |
|---|---|
| Pages (from-to) | 653-661 |
| Number of pages | 9 |
| Journal | New England Journal of Medicine |
| Volume | 346 |
| Issue number | 9 |
| DOIs | |
| Publication status | Published - Feb 28 2002 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Intravenous zoledronic acid in postmenopausal women with low bone mineral density. / Reid, Ian R.; Brown, Jacques P.; Burckhardt, Peter; Horowitz, Zebulun; Richardson, Peter; Trechsel, Ulrich; Widmer, Albert; Devogelaer, Jean Pierre; Kaufman, Jean Marc; Jaeger, Philippe; Body, Jean Jacques; Brandi, Maria Luisa; Broell, Johann; Micco, Raffaele Di; Genazzani, Andrea Riccardo; Felsenberg, Dieter; Happ, Joachim; Hooper, Michael J.; Ittner, Jochen; Leb, Georg; Mallmin, Hans; Murray, Timothy; Ortolani, Sergio; Rubinacci, Alessandro; Sääf, Maria; Samsioe, Goran; Verbruggen, Leon; Meunier, Pierre J.
In: New England Journal of Medicine, Vol. 346, No. 9, 28.02.2002, p. 653-661.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Intravenous zoledronic acid in postmenopausal women with low bone mineral density
AU - Reid, Ian R.
AU - Brown, Jacques P.
AU - Burckhardt, Peter
AU - Horowitz, Zebulun
AU - Richardson, Peter
AU - Trechsel, Ulrich
AU - Widmer, Albert
AU - Devogelaer, Jean Pierre
AU - Kaufman, Jean Marc
AU - Jaeger, Philippe
AU - Body, Jean Jacques
AU - Brandi, Maria Luisa
AU - Broell, Johann
AU - Micco, Raffaele Di
AU - Genazzani, Andrea Riccardo
AU - Felsenberg, Dieter
AU - Happ, Joachim
AU - Hooper, Michael J.
AU - Ittner, Jochen
AU - Leb, Georg
AU - Mallmin, Hans
AU - Murray, Timothy
AU - Ortolani, Sergio
AU - Rubinacci, Alessandro
AU - Sääf, Maria
AU - Samsioe, Goran
AU - Verbruggen, Leon
AU - Meunier, Pierre J.
PY - 2002/2/28
Y1 - 2002/2/28
N2 - Background. Bisphosphonates are effective agents for the management of osteoporosis. Their low bioavailability and low potency necessitate frequent administration on an empty stomach, which may reduce compliance. Gastrointestinal intolerance limits maximal dosing. Although intermittent intravenous treatments have been used, the optimal doses and dosing interval have not been systematically explored. Methods. We studied the effects of five regimens of zoledronic acid, the most potent bisphosphonate, on bone turnover and density in 351 postmenopausal women with low bone mineral density in a one-year, randomized, double-blind, placebo-controlled trial. Women received placebo or intravenous zoledronic acid in doses of 0.25 mg, 0.5 mg, or 1 mg at threemonth intervals. In addition, one group received a total annual dose of 4 mg as a single dose, and another received two doses of 2 mg each, six months apart. Lumbar-spine bone mineral density, was the primary end point. Results. There were similar increases in bone mineral density in all the zoledronic acid groups to values for the spine that were 4.3 to 5.1 percent higher than those in the placebo group (P
AB - Background. Bisphosphonates are effective agents for the management of osteoporosis. Their low bioavailability and low potency necessitate frequent administration on an empty stomach, which may reduce compliance. Gastrointestinal intolerance limits maximal dosing. Although intermittent intravenous treatments have been used, the optimal doses and dosing interval have not been systematically explored. Methods. We studied the effects of five regimens of zoledronic acid, the most potent bisphosphonate, on bone turnover and density in 351 postmenopausal women with low bone mineral density in a one-year, randomized, double-blind, placebo-controlled trial. Women received placebo or intravenous zoledronic acid in doses of 0.25 mg, 0.5 mg, or 1 mg at threemonth intervals. In addition, one group received a total annual dose of 4 mg as a single dose, and another received two doses of 2 mg each, six months apart. Lumbar-spine bone mineral density, was the primary end point. Results. There were similar increases in bone mineral density in all the zoledronic acid groups to values for the spine that were 4.3 to 5.1 percent higher than those in the placebo group (P
UR - http://www.scopus.com/inward/record.url?scp=0037186926&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037186926&partnerID=8YFLogxK
U2 - 10.1056/NEJMoa011807
DO - 10.1056/NEJMoa011807
M3 - Article
VL - 346
SP - 653
EP - 661
JO - New England Journal of Medicine
JF - New England Journal of Medicine
SN - 0028-4793
IS - 9
ER -